Jefferies Group reaffirmed their buy rating on shares of Verona Pharma (LON:VRP) in a research report released on Friday morning.
Separately, N+1 Singer lifted their price target on Verona Pharma from GBX 327 ($4.59) to GBX 348 ($4.88) and gave the stock a strong-buy rating in a research report on Wednesday, March 21st. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Verona Pharma currently has a consensus rating of Buy and a consensus target price of GBX 134.20 ($1.88).
Shares of Verona Pharma stock remained flat at $GBX 175 ($2.46) during trading on Friday. The stock had a trading volume of 16,971 shares, compared to its average volume of 49,797. Verona Pharma has a 52-week low of GBX 100 ($1.40) and a 52-week high of GBX 189 ($2.65).
Verona Pharma (LON:VRP) last issued its quarterly earnings results on Tuesday, February 27th. The company reported GBX (23.40) (($0.33)) EPS for the quarter, topping the Zacks’ consensus estimate of GBX (26.10) (($0.37)) by GBX 2.70 ($0.04).
WARNING: “Verona Pharma (VRP) Earns “Buy” Rating from Jefferies Group” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/verona-pharma-vrp-earns-buy-rating-from-jefferies-group.html.
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.